Teva may have new CEO on deck

Share this article:

Teva is rumored to be close to naming a new CEO, after a tumultuous few months that included the October announcement it was firing 10% of its staff, followed just weeks later with the public departure of then-CEO Jeremy Levin. Whether Levin was pushed or left on his own accord depends on the interviewee, but Eyal Deshesh has filled the role for the last several months.

Bloomberg reported Monday that board member Erez Vigodman is favored for the title, while BioCentury said Friday that Teva would not comment on whether the CEO of agrochemical firm Makhtshim Agan was in line for the job.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.